Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.
3.

Aflunov(®): a prepandemic influenza vaccine.

Gasparini R, Amicizia D, Lai PL, Panatto D.

Expert Rev Vaccines. 2012 Feb;11(2):145-57. doi: 10.1586/erv.11.170. Review.

PMID:
22309663
4.

[Tetravaccine--new fundamental approach to prevention of influenza pandemic].

Onishchenko GG, Zverev VV, Katlinskiĭ AV, Semchenko AV, Korovkin SA, Mel'nikov SIa, Mironov AN.

Zh Mikrobiol Epidemiol Immunobiol. 2007 Jul-Aug;(4):15-9. Review. Russian.

PMID:
17882832
5.

Monitoring the safety of annual and pandemic influenza vaccines: lessons from the US experience.

Iskander J, Broder K.

Expert Rev Vaccines. 2008 Feb;7(1):75-82. doi: 10.1586/14760584.7.1.75. Review.

PMID:
18251695
6.

Influenza vaccines: the good, the bad, and the eggs.

Schultz-Cherry S, Jones JC.

Adv Virus Res. 2010;77:63-84. doi: 10.1016/B978-0-12-385034-8.00003-X. Review.

PMID:
20951870
7.

Guillain-Barré syndrome after exposure to influenza virus.

Lehmann HC, Hartung HP, Kieseier BC, Hughes RA.

Lancet Infect Dis. 2010 Sep;10(9):643-51. doi: 10.1016/S1473-3099(10)70140-7. Review.

PMID:
20797646
8.

[Guillain-Barré syndrome after exposure to influenza].

Hartung HP, Keller-Stanislawski B, Hughes RA, Lehmann HC.

Nervenarzt. 2012 Jun;83(6):714-30. doi: 10.1007/s00115-012-3479-8. Review. German.

PMID:
22528062
9.

Preparing for a possible pandemic: influenza A/H5N1 vaccine development.

Keitel WA, Atmar RL.

Curr Opin Pharmacol. 2007 Oct;7(5):484-90. Review.

PMID:
17644429
10.

[Pandemic and prepandemic H5N1 influenza vaccines: a 2009 update].

Loulergue P, Launay O.

Med Sci (Paris). 2009 Aug-Sep;25(8-9):719-25. doi: 10.1051/medsci/2009258-9719. Review. French.

11.

Animal models for the preclinical evaluation of candidate influenza vaccines.

Bodewes R, Rimmelzwaan GF, Osterhaus AD.

Expert Rev Vaccines. 2010 Jan;9(1):59-72. doi: 10.1586/erv.09.148. Review.

PMID:
20021306
12.

Current status and progress of prepandemic and pandemic influenza vaccine development.

Leroux-Roels I, Leroux-Roels G.

Expert Rev Vaccines. 2009 Apr;8(4):401-23. doi: 10.1586/erv.09.15. Review.

PMID:
19348557
13.

Pandemic H5N1 influenza vaccine development: an update.

El Sahly HM, Keitel WA.

Expert Rev Vaccines. 2008 Mar;7(2):241-7. doi: 10.1586/14760584.7.2.241. Review.

PMID:
18324892
14.

Immunization-safety monitoring systems for the 2009 H1N1 monovalent influenza vaccination program.

Salmon DA, Akhtar A, Mergler MJ, Vannice KS, Izurieta H, Ball R, Lee GM, Vellozzi C, Garman P, Cunningham F, Gellin B, Koh H, Lurie N; H1N1 Working Group of Federal Immunization Safety Task Force..

Pediatrics. 2011 May;127 Suppl 1:S78-86. doi: 10.1542/peds.2010-1722L. Review.

PMID:
21502251
15.

DNA-based influenza vaccines: evaluating their potential to provide universal protection.

Choo AY, Broderick KE, Kim JJ, Sardesai NY.

IDrugs. 2010 Oct;13(10):707-12. Review.

PMID:
20878593
17.

A/H5N1 prepandemic influenza vaccine (whole virion, vero cell-derived, inactivated) [Vepacel®].

Plosker GL.

Drugs. 2012 Jul 30;72(11):1543-57. doi: 10.2165/11209650-000000000-00000. Review.

PMID:
22788239
18.

Progress with human H5N1 vaccines: a perspective from industry.

Palache B, Krause R.

Expert Rev Vaccines. 2009 Apr;8(4):391-400. doi: 10.1586/erv.09.16. Review.

PMID:
19348556
19.

Perspective: Swine-origin influenza: 1976 and 2009.

Sencer DJ.

Clin Infect Dis. 2011 Jan 1;52 Suppl 1:S4-7. doi: 10.1093/cid/ciq006. Review.

PMID:
21342898
20.

Preparing for avian influenza: lessons from the "swine flu affair".

Fineberg HV.

J Infect Dis. 2008 Feb 15;197 Suppl 1:S14-8. doi: 10.1086/524989. Review.

PMID:
18269322
Items per page

Supplemental Content

Support Center